No Data
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
Press Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation
No Data
